

### Elasomeran/tozinameran

**S**

#### **Cerebral venous sinus thrombosis: 3 case reports**

In a study of 2517 patients with adverse drug reactions after SARS-CoV-2 vaccination, reported to the EudraVigilance post-marketing module between 24 December 2020 and 8 April 2021, three patients [*ages and sexes not stated*] were described, who developed cerebral venous sinus thrombosis following SARS-CoV-2 vaccination with elasomeran or tozinameran [*dosages and routes not stated*].

The patients were vaccinated against SARS-CoV-2. One patient developed cerebral venous sinus thrombosis following administration of elasomeran [mRNA-1273] vaccine. Another two patients developed cerebral venous sinus thrombosis, 2 and 13 days after the second vaccination with tozinameran [BNT162b2 vaccine] [*outcomes not stated; not all duration of treatments to reactions onsets stated*].

Krzywicka K, et al. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. *European Journal of Neurology* 28: 3656-3662, No. 11, Nov 2021. Available from: URL: <https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.15029>

803642762